Steady-state Kinetics and Inhibitory Action of Antitubercular Phenothiazines on Mycobacterium tuberculosis Type-II NADH-Menaquinone Oxidoreductase (NDH-2)
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Type-II NADH-menaquinone oxidoreductase (NDH-2) is an essential respiratory enzyme of the pathogenic bacterium Mycobacterium tuberculosis (Mtb) that plays a pivotal role in its growth. In the present study, we expressed and purified highly active Mtb NDH-2 using a Mycobacterium smegmatis expression system, and the steady-state kinetics and inhibitory actions of phenothiazines were characterized. Purified NDH-2 contains a non-covalently bound flavin adenine dinucleotide cofactor and oxidizes NADH with quinones but does not react with either NADPH or oxygen. Ubiquinone-2 (Q2) and decylubiquinone showed high electron-accepting activity, and the steady-state kinetics and the NADH-Q2 oxidoreductase reaction were found to operate by a ping-pong reaction mechanism. Phenothiazine analogues, trifluoperazine, Compound 1, and Compound 2 inhibit the NADH-Q2 reductase activity with IC50 = 12, 11, and 13 microm, respectively. Trifluoperazine inhibition is non-competitive for NADH, whereas the inhibition kinetics is found to be uncompetitive in terms of Q2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![FIGURE 5 Hanes plots of the steady-state kinetics of the NADH-Q2 oxidoreductase activity of the purified Mtb NDH-2. Q2 reductase activities at various Q2 concentrations were plotted in a Hanes-Woolf plot ([Q2] versus [Q2]/ v ) and a Lineweaver-Burk plot (1/[Q2] versus 1/ v , inset ). NADH concentrations were varied: 10 𝛍 M ( closed square ), 20 𝛍 M ( open triangle ), 30 𝛍 M ( closed triangle ), 50 𝛍 M ( open circle ), and 100 𝛍 M ( closed circle ).](https://figures.cochat.ai/paper-figures/b925cfb0107748a485452f1156db312d/steady-state-kinetics-and-inhibitory-action-of-antitubercular-phenothiazines-on-figure-5.png)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NDH-2 has not been reported in mammalian mitochondria leading to the proposal that these enzymes may represent a potential drug target for the treatment of human pathogens (6, 12, 27, 30, 31) and intracellular parasites (32).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Assay of proteins in the presence of interfering materials
Bensadoun, A., & Weinstein, D. (1976) · Analytical Biochemistry · doi:10.1016/s0003-2697(76)80064-4 · Cited by 3,179
Genetic requirements for mycobacterial survival during infection
Sassetti, C. M., & Rubin, E. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134250100 · Cited by 1,354
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism
Boshoff, H. I. M., Myers, T. G., Copp, B. R., McNeil, M. R., Wilson, M. A., & Barry, C. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406796200 · Cited by 606
Messner, K. R., & Imlay, J. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10119 · Cited by 299
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs
Weinstein, E. A., Yano, T., Li, L.-S., Avarbock, D., Avarbock, A., Helm, D., McColm, A. A., Duncan, K., Lonsdale, J. T., & Rubin, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500469102 · Cited by 289
Self-citationA rapid micromethod for determination of FMN and FAD in mixtures
Faeder, E. J., & Siegel, L. M. (1973) · Analytical Biochemistry · doi:10.1016/0003-2697(73)90442-9 · Cited by 288
Altered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria
Vilchèze, C., Weisbrod, T. R., Chen, B., Kremer, L., Hazbón, M. H., Wang, F., Alland, D., Sacchettini, J. C., & Jacobs, W. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.708-720.2005 · Cited by 284
Research works printed but not linked: 3
- Molnar, J., Beladi, I., and Foldes, I. (1977) Zentralbl Bakteriol [Orig. A] 239, 521-526
- Kristiansen, J. E., and Vergmann, B. (1986) Acta Pathol. Microbiol. Immunol. Scand. B 94, 393-398
- Sambrook, J., Fritsch, E., and Maniatis, T. (eds) (1989) Molecular Cloning: A Labora- tory Manual, 2nd Ed., Cold spring Harbor Press, New York
Cited by
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
“Although there are currently no drugs approved for TB treatment that target mycobacterial NDH2, experimental observations with the NDH2 inhibitors phenothiazines, chlorpromazine and thioridazine (which are antipsychotic drugs) provide a case for targeting NDH2 (Ref”
Mycobacterium tuberculosis: success through dormancy
Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 696
“…Mtb remains sensitive to inhibition of NADH dehydrogenase 2, a single protein enzyme that can serve as alternate entry point of electrons into the electron transport chain but lacks proton translocation capacity (Xie et al., 2005; Yano et al., 2006; Teh et al., 2007; Gengenbacher et al., 2010).”
BackgroundRao, S. P. S., Alonso, S., Rand, L., Dick, T., & Pethe, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711697105 · Cited by 517
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase
Yano, T., Kassovska-Bratinova, S., Teh, J. S., Winkler, J., Sullivan, K., Isaacs, A., Schechter, N. M., & Rubin, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.200501 · Cited by 346
Self-citationSyntrophic butyrate and propionate oxidation processes: from genomes to reaction mechanisms
Müller, N., Worm, P., Schink, B., Stams, A. J. M., & Plugge, C. M. (2010) · Environmental Microbiology Reports · doi:10.1111/j.1758-2229.2010.00147.x · Cited by 326
“The electron transfer from butyrylCoA to external electron acceptors was found to be inhibited by trifluoperazine, a compound known to inhibit electron transfer to menaquinone by the respiratory complex I in Mycobacterium tuberculosis (Yano et al., 2006).”
BackgroundPhenothiazine: the seven lives of pharmacology's first lead structure
Ohlow, M. J., & Moosmann, B. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.001 · Cited by 280
Gengenbacher, M., Rao, S. P. S., Pethe, K., & Dick, T. (2010) · Microbiology · doi:10.1099/mic.0.033084-0 · Cited by 260
Small molecule selenium-containing compounds: Recent development and therapeutic applications
Chuai, H., Zhang, S.-Q., Bai, H., Li, J., Wang, Y., Sun, J., Wen, E., Zhang, J., & Xin, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113621 · Cited by 246
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
“However, NdhA is found to be nonessential in vitro and in vivo by transposon mutatgenesis [9,33], possibly due to redundancy with Ndh, the other type II NADH dehydrogenase in the Mtb genome (Rv1854c), which is essential [34].”
BackgroundDeris, Z. Z., Akter, J., Sivanesan, S., Roberts, K. D., Thompson, P. E., Nation, R. L., Li, J., & Velkov, T. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.111 · Cited by 216
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“, phenothiazine analogues, platanetin, quinolinyl pyrimidines) (12, 27, 33), but the mechanism of inhibition remains unknown.”
BackgroundKurosu, M., & Begari, E. (2010) · Molecules · doi:10.3390/molecules15031531 · Cited by 165
Martins, M., Dastidar, S. G., Fanning, S., Kristiansen, J. E., Molnar, J., Pagès, J.-M., Schelz, Z., Spengler, G., Viveiros, M., & Amaral, L. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.10.025 · Cited by 161
“[85] Yano T, Li LS, Weinstein E, Teh JS, Rubin H.”
BackgroundEnergy Metabolism and Drug Efflux in Mycobacterium tuberculosis
Black, P. A., Warren, R. M., Louw, G., van Helden, P. D., Victor, T. C., & Kana, B. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02293-13 · Cited by 180
“In addition to phenothiazines, which target the mycobacterial NDH-2, clofazimine (CFZ)—a rhiminophenazine—is subject to reduction by NDH-2 and, upon subsequent oxidation, leads to the formation of reactive oxygen species (88), which presumably contributes to its efficacy in mice (89).”
BackgroundHeikal, A., Nakatani, Y., Dunn, E., Weimar, M. R., Day, C. L., Baker, E. N., Lott, J. S., Sazanov, L. A., & Cook, G. M. (2014) · Molecular Microbiology · doi:10.1111/mmi.12507 · Cited by 147
“tuberculosis is inhibited by a range of phenothiazine analogues (antitubercular agents) at micromolar concentrations (Weinstein et al., 2005; Yano et al., 2006).”
BackgroundInfluentialGramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics
Mogi, T., & Kita, K. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0129-9 · Cited by 167
“Screening of a natural antibiotics library In order to identify new inhibitors for alternative respira- tory enzymes (i.e., enzymes that are not present in human mitochondria), we screened the Kitasato Institute for Life Sciences Chemical Library [30] with the following enzymes: cytochrome bd quinol oxidase from Esche…”
BackgroundInfluentialAmaral, L., Martins, M., & Viveiros, M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl500 · Cited by 150
“Since that demonstration, others have shown that derivatives of chlorpromazine could also reduce the number of organisms recovered from the lungs of the infected mouse.(76,77) Other phenothiazines have also been suggested for the management of tuberculosis.”
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0014-2016 · Cited by 141
“The Ndh and NdhA proteins of M. tuberculosis have been shown to be functional NADH dehydrogenases that transfer electrons to the quinone pool via a two-site ping-pong reaction mechanism (23, 24).”
BackgroundAntituberculosis Drug Research: A Critical Overview
Beena, & Rawat, D. S. (2012) · Medicinal Research Reviews · doi:10.1002/med.21262 · Cited by 139
Energetics of Pathogenic Bacteria and Opportunities for Drug Development
Cook, G. M., Greening, C., Hards, K., & Berney, M. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.001 · Cited by 147
“appear to involve competitive inhibition of NADH or quinone binding (Weinstein et al., 2005; Yano et al., 2006).”
BackgroundIwata, M., Lee, Y., Yamashita, T., Yagi, T., Iwata, S., Cameron, A. D., & Maher, M. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210059109 · Cited by 113
“The NDH-2 enzymes have also emerged as potential therapeutic targets for treatments against the causative agents of malaria (Plasmodium falciparum) (11–13) and tuberculosis (Mycobacterium tuberculosis) (14, 15).”
BackgroundNitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration
Sohaskey, C. D. (2008) · Journal of Bacteriology · doi:10.1128/jb.01857-07 · Cited by 108
“tuberculosis (1, 4) by targeting the type II NADH dehydrogenase (30, 31), succinate dehydrogenase (7), and the binding of calcium to proteins (2).”
BackgroundDutta, N. K., Mehra, S., & Kaushal, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010069 · Cited by 116
Amaral, L., & Viveiros, M. (2017) · Antibiotics · doi:10.3390/antibiotics6010003 · Cited by 101
The Mycobacterium tuberculosis High-Affinity Iron Importer, IrtA, Contains an FAD-Binding Domain
Ryndak, M. B., Wang, S., Smith, I., & Rodriguez, G. M. (2010) · Journal of Bacteriology · doi:10.1128/jb.00223-09 · Cited by 96
“Membranes were isolated as described previously (31), and”
MethodSaleh, A., Friesen, J., Baumeister, S., Groß, U., & Bohne, W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00895-06 · Cited by 106
“interfere with Mycobacterium tuberculosis growth (26, 27).”
Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents
Shirude, P. S., Paul, B., Choudhury, N. R., Kedari, C. K., Bandodkar, B., & Ugarkar, B. G. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300134b · Cited by 102
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Bald, D., & Koul, A. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01959.x · Cited by 94
Murugesan, D., Ray, P. C., Bayliss, T., Prosser, G. A., Harrison, J. R., Green, K., de Melo, C. S., Feng, T., Street, L. J., Chibale, K., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00275 · Cited by 89
The mechanism of catalysis by type-II NADH:quinone oxidoreductases
Blaza, J. N., Bridges, H. R., Aragão, D., Dunn, E. A., Heikal, A., Cook, G. M., Nakatani, Y., & Hirst, J. (2017) · Scientific Reports · doi:10.1038/srep40165 · Cited by 76
Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence
Vilchèze, C., Weinrick, B. C., Leung, L. W., & Jacobs, W. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721545115 · Cited by 89
“It may suggest that, although NdhA is an active NADH dehydrogenase during log phase, its ability to oxidize NADH into NAD+ might be reduced during lag phase.”
BackgroundInfluentialReddyrajula, R., Dalimba, U., & Kumar, S. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.010 · Cited by 81
Function, kinetic properties, crystallization, and regulation of microbial malate dehydrogenase
Takahashi-Íñiguez, T., Aburto-Rodríguez, N. A., Vilchis-González, A. L., & Flores, M. E. (2016) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1500219 · Cited by 79
“…called malate:quinone oxidoreductase (MQO; EC 1.1.99.16), catalyzes the same reaction as MDH in Azotobacter (Jurtshuk et al., 1969), Mycobacterium (Yano et al., 2006), Micrococcus (Cohn, 1956), B. subtilis (Bergsma et al., 1982), C. glutamicum (Molenaar et al., 1998), E. coli (van der Rest et…”
BackgroundInfluentialSmall, J. L., Park, S. W., Kana, B. D., Ioerger, T. R., Sacchettini, J. C., & Ehrt, S. (2013) · mBio · doi:10.1128/mbio.00475-13 · Cited by 79
“(11, 33, 34), was not different from that of the WT and the CcsXcomp mutant, suggesting that type II NADH dehydrogenase activity is not decreased in the mutant.”
The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis.
Martins, M., Viveiros, M., Kristiansen, J. E., Molnar, J. A., & Amaral, L. (2007) · PubMed · Cited by 81
Schurig-Briccio, L. A., Yano, T., Rubin, H. N., & Gennis, R. B. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.03.017 · Cited by 81
“tuberculosis and to have antitubercular activity [14,17,27], also have antibacterial activity against MRSA [28].”
Self-citationMogi, T., Murase, Y., Mori, M., Shiomi, K., Ōmura, S., Paranagama, M. P., & Kita, K. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp096 · Cited by 72
Madrid, P. B., Polgar, W. E., Toll, L., & Tanga, M. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.064 · Cited by 71
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 68
“ot er re ort s ests t at cyd s orts co acterial ersiste ce i I -treate ice [13].”
BackgroundInfluentialAntitubercular pharmacodynamics of phenothiazines
Warman, A. J., Rito, T., Fisher, N. E., Moss, D. M., Berry, N. G., O’Neill, P. M., Ward, S. A., & Biagini, G. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks483 · Cited by 71
Sena, F. V., Batista, A. P., Catarino, T., Brito, J. A., Archer, M., Viertler, M., Madl, T., Cabrita, E. J., & Pereira, M. M. (2015) · Molecular Microbiology · doi:10.1111/mmi.13120 · Cited by 79
“, 2005), Mycobacterium tuberculosis (Yano et al., 2006) and S.”
BackgroundMarreiros, B. C., Sena, F. V., Sousa, F. M., Batista, A. P., & Pereira, M. M. (2016) · Environmental Microbiology · doi:10.1111/1462-2920.13352 · Cited by 68
Bartek, I. L., Reichlen, M. J., Honaker, R. W., Leistikow, R. L., Clambey, E. T., Scobey, M. S., Hinds, A., Born, S. E. M., Covey, C. R., Schurr, M. J., et al. (2016) · mSphere · doi:10.1128/msphere.00176-16 · Cited by 60
Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Hasenoehrl, E., Wiggins, T. J., & Berney, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.611683 · Cited by 62
“PTZs completely inhibited activity of recombinantly expressed and purified Ndh and NdhA (Weinstein et al., 2005; Yano et al., 2006).”
BackgroundInfluentialYano, T., Rahimian, M., Aneja, K. K., Schechter, N. M., Rubin, H. N., & Scott, C. P. (2014) · Biochemistry · doi:10.1021/bi4013897 · Cited by 57
Self-citationIdentification of new inhibitors for alternative NADH dehydrogenase (NDH-II)
Mogi, T., Matsushita, K., Murase, Y., Kawahara, K., Miyoshi, H., Ui, H., Shiomi, K., Ōmura, S., & Kita, K. (2008) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2008.01451.x · Cited by 56
“5), which are better than 12mM of trifluoperazine for M. tuberculosis NDH-II (Yano et al., 2006).”
BackgroundPetri, J., Shimaki, Y., Jiao, W., Bridges, H. R., Russell, E. R., Parker, E. J., Aragão, D., Cook, G. M., & Nakatani, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.03.014 · Cited by 53
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives
Bate, A. B., Kalin, J. H., Fooksman, E. M., Amorose, E. L., Price, C. M., Williams, H., Rodig, M. J., Mitchell, M. O., Cho, S., Wang, Y., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.091 · Cited by 50
Yamashita, T., Nakamaru‐Ogiso, E., Miyoshi, H., Matsuno‐Yagi, A., & Yagi, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610646200 · Cited by 48
Activation of type II NADH dehydrogenase by quinolinequinones mediates antitubercular cell death
Heikal, A., Hards, K., Cheung, C., Menorca, A., Timmer, M. S. M., Stocker, B. L., & Cook, G. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw244 · Cited by 48
Dunn, E. A., Roxburgh, M., Larsen, L., Smith, R. A. J., McLellan, A. D., Heikal, A., Murphy, M. P., & Cook, G. M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.050 · Cited by 53
Martins, M., Viveiros, M., & Amaral, L. (2008) · PubMed · Cited by 53
Lencina, A. M., Franza, T., Sullivan, M. J., Ulett, G. C., Ipe, D. S., Gaudu, P., Gennis, R. B., & Schurig-Briccio, L. A. (2018) · mBio · doi:10.1128/mbio.01034-18 · Cited by 47
“These small enzymes, with binding sites for both NADH and quinol, appear to be susceptible to inhibitors that do not bind at the substrate binding sites but, rather, to allosteric sites (44).”
BackgroundAdvances in Key Drug Target Identification and New Drug Development for Tuberculosis
Mi, J., Gong, W., & Wu, X. (2022) · BioMed Research International · doi:10.1155/2022/5099312 · Cited by 48
“Several compounds, such as phenothiazines, quinoline pyrimidines, quinazolones, and diphenyl iodine (DPI) analogs, have been found to be potent inhibitors of this enzyme [91 – 94].”
Müller, N., Schleheck, D., & Schink, B. (2009) · Journal of Bacteriology · doi:10.1128/jb.01605-08 · Cited by 49
Identifying Metabolic Inhibitors to Reduce Bacterial Persistence
Mohiuddin, S. G., Hoàng, T., Saba, A., Karki, P., & Orman, M. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00472 · Cited by 43
“In Mycobacterium tuberculosis, phenothiazines inhibit cellular respiration, leading to depletion of ATP as well as the reduction of NADH/NAD+ and menaquinol/menaquinone ratios (Boshoff et al., 2004; Weinstein et al., 2005; Yano et al., 2006).”
BackgroundResultInfluentialAnand, P., & Akhter, Y. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.05.124 · Cited by 44
Fisher, N. E., Warman, A. J., Ward, S. A., & Biagini, G. A. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)04417-0 · Cited by 44
“There is limited steady-state kinetic information regarding this class of enzyme, but one study indicates that the reaction kinetics of type II NADH: quinone oxidoreductases operate a ping-pong (double displacement) mechanism, whereby one product is released from the enzyme before all of the substrates have bound (Yan…”
BackgroundSellamuthu, S., Singh, M., Kumar, A., & Singh, S. K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1327577 · Cited by 40
Dutta, N. K., Pinn, M. L., & Karakousis, P. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02981-14 · Cited by 36
Yu, Y., Yamashita, T., Nakamaru‐Ogiso, E., Hashimoto, T., Murai, M., Igarashi, J., Miyoshi, H., Mori, N., Matsuno‐Yagi, A., Yagi, T., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175547 · Cited by 36
Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis
de Keijzer, J., Mulder, A., de Haas, P. E. W., de Ru, A. H., Heerkens, E. M., Amaral, L., van Soolingen, D., & van Veelen, P. A. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01037 · Cited by 39
Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro
Awasthy, D., Ambady, A., Narayana, A., Morayya, S., & Sharma, U. K. (2014) · Gene · doi:10.1016/j.gene.2014.08.024 · Cited by 40
“This meant that despite showing similar types of biochemical activities (Yano et al., 2006), Ndh and NdhAmight be playing different roles in the physiology of the organism.”
BackgroundInfluentialDutta, N. K., Mazumdar, K., Dastidar, S. G., Karakousis, P. C., & Amaral, L. (2011) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489111796064597 · Cited by 37
“This would explain the induction of Rv2745c in response to THZ, a drug that disrupts bacterial redox potential by inactivating NADH dehydrogenase [24, 56, 82, 83].”
BackgroundInfluentialPhenothiazines as anti-tubercular agents: mechanistic insights and clinical implications
Sharma, S., & Singh, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.628657 · Cited by 37
Unprecedented Properties of Phenothiazines Unraveled by a NDH-2 Bioelectrochemical Assay Platform
Nakatani, Y., Shimaki, Y., Dutta, D., Muench, S. P., Ireton, K., Cook, G. M., & Jeuken, L. J. C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10254 · Cited by 35
Activity of Trifluoperazine against Replicating, Non-Replicating and Drug Resistant M. tuberculosis
Advani, M. J., Siddiqui, I., Sharma, P., & Reddy, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044245 · Cited by 34
“NDH-2 is required to sustain ATP homeostasis during dormancy [37] whereas MCAT is involved in fatty acid synthesis [38], which is the major nutrient source for M.”
BackgroundKawahara, K., Mogi, T., Tanaka, T., Hata, M., Miyoshi, H., & Kita, K. (2008) · The Journal of Biochemistry · doi:10.1093/jb/mvn161 · Cited by 34
“in terms of Q2 for Mycobacterium tuberculosis NDH-II (IC50 = 12 mM) (42), reduced the NADH:Q1 reductase activity to 26% of the control at 100 mM.”
BackgroundMohiuddin, S. G., Nguyen, T. V., & Orman, M. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03172-8 · Cited by 34
Antimicrobial Potential of Quaternary Phosphonium Salt Compounds: a Review
Ibrahim, M. K., Haria, A., Mehta, N. V., & Degani, M. S. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0188 · Cited by 34
Nizi, M. G., Desantis, J., Nakatani, Y., Massari, S., Mazzarella, M. A., Shetye, G. S., Sabatini, S., Barreca, M. L., Manfroni, G., Felicetti, T., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112420 · Cited by 31
“targeting the type II NADH dehydrogenase (NDH-2).[22] NDH-2 is a membrane-bound bisubstrate enzyme that catalyzes the cytoplasmic oxidation of NADH to NAD + , followed by the reduction of quinone to quinol in the membrane in the presence of flavin adenine dinucleotide (FAD) co‐factor.”
BackgroundGupta, V. K., Kumar, M. M., Singh, D. K., Bisht, D., & Sharma, S. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1377346 · Cited by 30
Regulation of the mechanism of Type-II NADH: Quinone oxidoreductase from S. aureus
Sena, F. V., Sousa, F. M., Oliveira, A. S. F., Soares, C. M., Catarino, T., & Pereira, M. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.02.004 · Cited by 29
Mycobacterial MenJ: An Oxidoreductase Involved in Menaquinone Biosynthesis
Upadhyay, A., Kumar, S., Rooker, S. A., Koehn, J. T., Crans, D. C., McNeil, M., Lott, J. S., & Crick, D. C. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00402 · Cited by 31
Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery
Lou, Z., & Zhang, X. (2010) · Protein & Cell · doi:10.1007/s13238-010-0057-3 · Cited by 29
“Menaquinone is reported to be essential forM. tuberculosis growth (Weinstein et al., 2005; Yano et al., 2006; Teh et al., 2007).”
BackgroundCurrent Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets
Fernandes, G., Jornada, P. D., de Souza, C. O., Chin, C. M., Pavan, F. R., & dos Santos, J. L. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150818103836 · Cited by 29
“drugs in TB therapy is limited due to adverse effects [102].”
BackgroundChen, B.-C., Ding, Z., Dai, J.-S., Chen, N.-P., Gong, X., Ma, L., & Qian, C. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.647289 · Cited by 28
Duarte, M., Ferreira, C. E., Khandpur, G. K., Flohr, T., Zimmermann, J., Castro, H., Herrmann, J. M., Morgan, B., & Tomás, A. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103803118 · Cited by 24
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 24
Structure of the Ndi1 protein from Saccharomyces cerevisiae in complex with myxothiazol.
Yamashita, T., Inaoka, D. K., Shiba, T., Oohashi, T., Iwata, S., Yagi, T., Kosaka, H., Miyoshi, H., Harada, S., Kita, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20775-6 · Cited by 22
ATP synthesis driven by atmospheric hydrogen concentrations
Soom, S., Moning, S. U., Cook, G. M., Lingford, J. P., Kropp, A., Tran, S. L., Grinter, R., Greening, C., & von Ballmoos, C. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506353122 · Cited by 22
“1,2 - dioleoyl - sn - glycero - 3 - phosphocholine [18:1 ( Δ 9 - cis)] (DOPC), 1,2 - dioleoyl - sn - glycero - 3 - phosphoethanolamine [18:1 ( Δ 9 - cis)] (DOPE) and 1,2 - dioleoyl - sn - glycero - 3 - phospho - (1 ′-rac - glycerol) [18:1 ( Δ 9 - cis)] (DOPG) were obtained from Avanti Polar Lipids…”
Maeda, T., Kawada, M., Sakata, N., Kotani, H., & Furusawa, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94645-z · Cited by 21
Liu, J., KRULWICH, T. A., & Hicks, D. B. (2008) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.02.004 · Cited by 21
“Thus like most reported type II NADH dehydrogenases [8,14,17,28,29], both NDH-2A and NDH-2B contain non-covalently bound FAD as a prosthetic group.”
BackgroundAmaral, L., & Molnar, J. A. (2012) · PubMed · Cited by 25
Reichlen, M. J., Leistikow, R. L., Scobey, M. S., Born, S. E. M., & Voskuil, M. I. (2017) · Journal of Bacteriology · doi:10.1128/jb.00320-17 · Cited by 22
“We examined the role of the electron transport system using the phenothiazine chlorpromazine (CPZ), a proposed inhibitor of the membranebound type 2 NADH dehydrogenase (Ndh2) (38, 39).”
MethodCurrent possibilities and unresolved issues of drug target validation inMycobacterium tuberculosis
Sharma, U. K. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.626763 · Cited by 20
“Chemical validation involving inhibitors active on multiple orthologs [6,68] will, particularly, be of value Table 3.”
BackgroundNovel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication
Salie, S., Hsu, N., Semenya, D., Jardine, A. M., & Jacobs, M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku036 · Cited by 19
Lu, L., Åkerbladh, L., Ahmad, S., Konda, V., Cao, S., Vocat, A., Maes, L. J. R. M., Cole, S. T., Hughes, D., Larhed, M., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00413 · Cited by 20
A simple assay for inhibitors of mycobacterial oxidative phosphorylation
Harden, S. A., Courbon, G. M., Liang, Y., Kim, A. S., & Rubinstein, J. L. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105483 · Cited by 14
“The assay also shows that thioridazine (THZ), a first generation antipsychotic drug that was found to inhibit mycobacterial NDH-2 (Rao et al., 2008; Weinstein et al., 2005; Yano et al., 2006), functions as an uncoupler of the PMF at micromolar concentrations.”
BackgroundInfluentialda Silva, P. E. A., Machado, D., Ramos, D. F., Couto, I., von Groll, A., & Viveiros, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-39658-3_21 · Cited by 25
Substrate–Protein Interactions of Type II NADH:Quinone Oxidoreductase from Escherichia coli
Salewski, J., Batista, A. P., Sena, F. V., Millo, D., Zebger, I., Pereira, M. M., & Hildebrandt, P. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00070 · Cited by 18
Ruth, M. M., Pennings, L. J., Koeken, V. A. C. M., Schildkraut, J. A., Hashemi, A., Wertheim, H. F. L., Hoefsloot, W., & van Ingen, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00181-20 · Cited by 17
“It inhibits its efflux pumps and blocks its respiratory chain (6).”
BackgroundUnderstanding the Pathophysiology of the Human TB Lung Granuloma using in Vitro Granuloma Models
Bhavanam, S., Rayat, G. R., Keelan, M., Kunimoto, D. Y., & Drews, S. J. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0005 · Cited by 17
New antituberculosis drugs targeting the respiratory chain
Li, Q., & Lu, X. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.04.007 · Cited by 17
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch14 · Cited by 18
Parumasivam, T., Chan, J. G. Y., Pang, A., Quan, D. H., Triccas, J. A., Britton, W. J., & Chan, H. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.07.014 · Cited by 18
Lima, W. G., Ramos-Alves, M. C., & Soares, A. C. (2019) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v48n1.80062 · Cited by 17
“tuberculosis em concentrações a partir de1 μg/mL, a qual é 10 vezes superior a comumente encontrada no plasma após uma dose usual desse fármaco [78-85].”
BackgroundMcNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 15
“Phenothiazinelike compounds including CFZ have long been thought to kill through a redox cycle involving reduction by NDH-2 and spontaneous re-oxidation by O2, producing toxic levels of ROS (Yano et al., 2006; Yano et al., 2011; Heikal et al., 2016).”
BackgroundInfluentialTran, P. L., Kopel, J. J., Ristić, B., Marsh, H. D., Fralick, J. A., & Reid, T. W. (2022) · Advances in Redox Research · doi:10.1016/j.arres.2022.100031 · Cited by 14
Metadata
- Authors
- Yano, T., Li, L.-S., Weinstein, E., Teh, J.-S., & Rubin, H.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Rubin, Harvey
- ORCID
- Rubin, Harvey
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 281
- Issue
- 17
- Pages
- 11456-11463
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2040519812
- Cited by
- 150
- References
- 38
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 3 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 6 · 2014: 16 · 2013: 4 · 2012: 11
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5296 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI043420, AI-43420)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- Mycobacterium tuberculosis, NDH-2, phenothiazines, antitubercular agents, enzyme inhibition kinetics, ping-pong mechanism, trifluoperazine, non-competitive inhibition
- MeSH terms
- Antitubercular Agents, Binding, Competitive, Enzyme Inhibitors, Flavin-Adenine Dinucleotide, Kinetics, Mycobacterium tuberculosis, NAD, Phenothiazines, Quinone Reductases, Quinones, Ubiquinone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.